Viyash Scientific Limited, through its wholly owned subsidiary Alivira Animal Health Limited, has signed a binding agreement to acquire 100% of Italy-based BioForLife Italia S.r.l. (BFL) for approximately Rs. 188 crore, marking a significant expansion of its global companion animal health business.

The acquisition, expected to close in the second quarter of FY27, aligns with Viyash’s strategy to capitalize on the rapidly growing companion animal health generics market while strengthening its foothold in Europe’s pet care sector. 

BioForLife, headquartered in Milan, specializes in the development, commercialization and distribution of pet healthcare products. The company has built a strong presence in Italy through a diverse portfolio spanning nutritional supplements, pharmaceuticals and rapid diagnostic tests for companion animals. It is also expanding into high-growth therapeutic areas such as dermatology and ophthalmology.

Italy ranks among the five largest animal health markets in Europe, with companion animal care emerging as one of the fastest-growing segments. Growth is being fueled by increasing pet ownership, the rising trend of pet humanization and greater spending on preventive and specialized veterinary care. 

BioForLife’s established commercial network is one of the key attractions of the deal. The company’s sales team reaches more than 80% of veterinary clinics across Italy, providing deep customer relationships and a strong platform for future expansion.

The acquisition is expected to create significant synergies between the two companies. Alivira plans to use BioForLife’s commercial infrastructure to introduce products from its companion animal pipeline into the Italian market, while leveraging its own international presence to expand BioForLife’s product range across Europe, the Middle East, Asia and Latin America.

Dr. Haribabu Bodeputi, Managing Director and Group CEO of Viyash Scientific Limited, said the transaction represents another milestone in the company’s ambition to build a leading global companion animal health business. 

“This acquisition represents another important step in our strategy to build a leading global Companion Animal Health business. BioForLife provides us with an established platform in Italy, one of Europe's most attractive pet care markets, while strengthening our presence across the region.”

He added that combining BioForLife’s market access with Alivira’s product development capabilities would create a strong foundation for growth.

“The combination of BioForLife's commercial reach and Alivira's product development capabilities creates a compelling opportunity to accelerate growth, expand our companion animal portfolio and deliver greater value to veterinarians, pet owners and partners across markets.” 

Dr. Bodeputi also highlighted the potential to introduce innovative pet healthcare products into India and other international markets through the company’s expanding global network.

“We also see meaningful opportunities to introduce innovative products into India and other geographies through our global reach. This investment reflects our continued commitment to sustainable growth, strategic expansion and long-term value creation.”